Day: April 29, 2020

VANCOUVER, Washington, April 29, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic services provider and an advisor to CytoDyn, will provide a comprehensive update on leronlimab for COVID-19. The Wall Street Reporter’s event is scheduled for Friday, May 1, 2020 at 12:30 pm ET / 9:30 am PT.Dr. Pourhassan will provide an update on patient enrollment in eIND, Phase 2 and Phase 2b/3 COVID-19 trials. Dr. Patterson will discuss his latest discovery of the mechanism of action of COVID-19...

Paris, Amsterdam, April 29, 2020           Press releaseFinancial information as at March 31, 2020URW reports total turnover through March 31, 2020: +1.8%.The quarter was marked by the initial impact of the COVID-19 outbreak, affecting primarily the Convention & Exhibition business in France and retail activity in parts of Europe.As from April 20, progressive reopening has started in Germany. Austria is expected to follow on May 2, Poland on May 4, France(1), the Czech Republic and Denmark on May 11, and Spain between May 24 and June 3.Through February 29, the Group’s tenant sales were up by +2.8%, of which +3.3% in Europe and +1.6% in the US.TurnoverThe proportionate turnover of Unibail-Rodamco-Westfield (“URW” or the “Group”) for the first three months of 2020 amounted to €956.6 Mn, up by +1.8%, mainly due to the property development...

HAMPTON, N.H., April 29, 2020 (GLOBE NEWSWIRE) — Unitil Corporation (NYSE:UTL) (www.unitil.com) held its Annual Meeting of Shareholders today at the corporate office in Hampton, New Hampshire. Shareholders elected Winfield S. Brown, Mark H. Collin and Michael B. Green to the Board of Directors each for a term of three years. Shareholders also ratified the selection of Deloitte & Touche, LLP as independent registered public accountants for 2020.  Additionally, the required shareholder advisory vote concerning executive compensation, also known as “say on pay,” was approved by 95% of shareholders.About Unitil CorporationUnitil Corporation provides energy for life by safely and reliably delivering natural gas and electricity in New England. We are committed to the communities we serve and to developing people, business practices,...

.AttachmentSveitarfélagið Árborg ársreikningur 2019 fyrri umræða

. ViðhengiSveitarfélagið Árborg ársreikningur 2019 fyrri umræða

– A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study –NEWTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that its late-breaking abstract detailing results from the pivotal, Phase 3 BOSTON study has been selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program taking place May 29-31, 2020.  The BOSTON study is evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have...

BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for its ongoing Phase II study of oral paclitaxel and encequidar (Oral Paclitaxel; formerly known as Oraxol), for the treatment of angiosarcoma, has been accepted for presentation in a poster discussion session at the American Society of Clinical Oncology’s (ASCO) upcoming ASCO20 Virtual Scientific Program, to be held from May 29 to May 31, 2020.Presentation details are as follows:Title: (Abstract 11517) A Phase II Study of Oraxol in the Treatment of Unresectable Cutaneous AngiosarcomaPoster Session: SarcomaLocation: ASCO Virtual Scientific ProgramThis Phase...

TORONTO, April 29, 2020 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (the “Company”) (CSE: IDK), at the request of the Market Surveillance Group of the Investment Industry Regulatory Organization of Canada (IIROC), announces that the Company’s management is not aware of any material undisclosed information that would account for the recent level of trading activity of its shares on the Canadian Securities Exchange.About ThreeD Capital Inc.ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the Junior Resources, Artificial Intelligence and Blockchain sectors.  ThreeD seeks to invest in early stage, promising companies and ICOs where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s ecosystem.Forward-Looking...

Los Angeles, CA, April 29, 2020 (GLOBE NEWSWIRE) — Los Angeles, California /GLOBENEWSWIRE/- April 29, 2020. KRONOS ADVANCED TECHNOLOGIES, Inc., (OTC:KNOS) (“KNOS” or the “Company”) a product development and production company that has significantly changed the way air is moved, filtered and sterilized today announced  new products in its collection of air purifiers, KRONOS® AIG 5G® MODEL 3 and MODEL 8. Powered by Kronos CORE Technology, Model 3 is scaled-down version of a popular Model 5 and includes the same advanced features such as laser particulate matter sensor, several fan speeds, WIFI module and other useful features.With these features, Model 3 and Model 8 can be operated 24/7 using from only 30 watts of energy to reduce noise and the amount of infectious particulates in the indoor air, like worst...